Dreamgenics and Retina Bizkaia Begisare have signed a framework agreement to collaborate on initiatives that contribute to improving understanding and diagnosis of hereditary retinal dystrophies. The agreement, signed by Arantza Uliarte, president of the association, and Carlos Martínez Laborde, CEO of Dreamgenics, covers the scientific, educational, and research fields.
Hereditary retinal dystrophies are a group of rare genetic disorders that cause progressive vision loss and affect approximately one in every 3,000 to 4,000 people. This category includes retinitis pigmentosa, Stargardt disease, Usher syndrome, and Leber congenital amaurosis, among others. Identifying the exact cause is not straightforward: more than 250 genes have been identified as involved, and the same clinical presentation can result from mutations in very different genes; consequently, next-generation sequencing (NGS) and bioinformatics analysis have become the standard approach for determining the cause.
In practice, the agreement makes Dreamgenics’ expertise in genomic analysis available to members and their families, both in conducting genetic testing and in providing counseling before and after the analysis, which may also be extended to their doctors upon request. “We are very pleased to have signed this agreement with Dreamgenics and to be able to draw on their expertise to continue improving the support we offer our members and their families, especially in terms of access to genetic testing,” says Arantza Uliarte.
Retina Bizkaia Begisare was founded in 2016 on the initiative of a group of people affected by these conditions who wanted to extend to Bizkaia the work that was already being done in Gipuzkoa. Since then, it has been working to improve the quality of life of those living with these conditions and their families by providing care, support, and information; organizing awareness-raising activities; and promoting research. Together with Retina Araba and Retina Gipuzkoa, it is part of Retina Euskadi Begisare.
The partnership between a patient organization and a company specializing in genomics was formed with the goal of making a direct impact on those living with these diseases. Both organizations will also be able to jointly promote scientific and research projects, as well as educational activities aimed at patients, families, and healthcare professionals. “This agreement builds on the work that Dreamgenics has been carrying out alongside other associations for hereditary retinal dystrophies. We want to continue forging partnerships like this one to help those affected and their families find a genetic explanation for their condition,” says Carlos Martínez.
With this agreement, both organizations are reinforcing their commitment to ensuring access to genetic testing as a means of making progress in addressing these diseases.